, Columnist
Got $10 Billion? Don’t Blow It Cloning a Woolly Mammoth.
Sure, it sounds cool. But think of the life-changing problems that could be solved with that kind of investment.
Cute or creepy?
Photo courtesy of Colossal Biosciences
This article is for subscribers only.
As if the 2020s weren’t weird enough, we might see woolly mammoths pounding across the tundra by this decade’s close.
Colossal Biosciences, a Dallas-based biotechnology and genetic engineering startup valued at $10 billion, has raised $435 million to “de-extinct” the woolly mammoth, a species that hasn’t walked the Earth in over 4,000 years. The company also plans to clone a dodo bird and a Tasmanian tiger.